Vortex Energy Aktie - VRTX

Rendering Error

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,075

Gebot

0,085

Fragen

0,09

Volumen

74.166

0,075 Tagesbereich 0,075

0,04 52-Wochen-Bereich 0,28

Handelsende

0,07

Handelsbeginn

0,075

Letzte Trade

359

0.08

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

75.035

Finanzvolumen

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.005	7.14285714286	0.07	0.075	0.06	13259	0.06741161	CS
4	-0.015	-16.6666666667	0.09	0.145	0.06	27898	0.08008515	CS
12	0.025	50	0.05	0.15	0.04	75035	0.06182165	CS
26	-0.035	-31.8181818182	0.11	0.15	0.04	111997	0.061532	CS
52	-0.195	-72.2222222222	0.27	0.28	0.04	91101	0.1103421	CS
156	-0.025	-25	0.1	2.32	0.04	185038	0.8480778	CS
260	-0.025	-25	0.1	2.32	0.04	185038	0.8480778	CS

VRTX - Frequently Asked Questions (FAQ)

What is the current Vortex Energy share price?

The current share price of Vortex Energy is $ 0,075

What is the 1 year trading range for Vortex Energy share price?

Vortex Energy has traded in the range of $ 0,04 to $ 0,28 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
FUTRGold n Futures Mineral Corp	$ 0,01 (100,00%)	17,56k
PDFIProphecy DeFi Inc	$ 0,01 (100,00%)	39k
CATCAT Strategic Metals Corporation	$ 0,01 (100,00%)	247k
XTRXAdastra Holdings Ltd	$ 0,46 (58,62%)	500
NIRVNirvana Life Sciences Inc	$ 0,15 (50,00%)	2,5k
LTHMChampion Electric Metals Inc	$ 0,005 (-50,00%)	7,08M
FFNT4Front Ventures Corp	$ 0,015 (-40,00%)	9k
GLDSGolden Spike Resources Corp	$ 0,025 (-28,57%)	1,43M
AITTTrenchant Technologies Capital Corp	$ 0,07 (-26,32%)	81k
TGIITrojan Gold Inc	$ 0,015 (-25,00%)	9k
LTHMChampion Electric Metals Inc	$ 0,005 (-50,00%)	7,08M
QIMCQuebec Innovative Materials Corp	$ 0,245 (0,00%)	2,13M
SOLSOL Global Investments Corp	$ 0,09 (-14,29%)	1,99M
CACRKWG Resources Inc	$ 0,035 (0,00%)	1,74M
GLDSGolden Spike Resources Corp	$ 0,025 (-28,57%)	1,43M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Vortex Energy Corp (VRTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

VRTX Neueste Nachrichten

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

VRTX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Vortex Energy Corp (VRTX) Börsenkurse

Vortex Energy Corp (VRTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

VRTX Neueste Nachrichten

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

VRTX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen